Cogent Biosciences
COGT
195 hedge funds and large institutions have $2.29B invested in Cogent Biosciences in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 87 increasing their positions, 46 reducing their positions, and 24 closing their positions.
167% more call options, than puts
Call options by funds: $20.7M | Put options by funds: $7.76M
135% more capital invested
Capital invested by funds: $973M → $2.29B (+$1.31B)
89% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 46
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
20.81% more ownership
Funds ownership: 119.04% → 139.85% (+21%)
8% more funds holding
Funds holding: 180 → 195 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$76M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.1M |
| 3 |
CC
Commodore Capital
New York
|
+$58.5M |
| 4 |
RI
RTW Investments
New York
|
+$41.1M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$32.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$85.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.5M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$22.1M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$19.7M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$12.5M |
COGT Hedge Fund Activity: Q3 2025 in Review
195 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2025, worth a combined $2.29B — up 135% from $973M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new COGT positions and 24 closed out — a net gain of 17 holders — while 87 added to existing stakes and 46 trimmed.
The largest buyer was Deerfield Management, adding an estimated $76M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $85.3M.
- 195 institutional investors held Cogent Biosciences (COGT) as of Q3 2025, up from 180 in Q2 2025.
- Funds reported $2.29B of Cogent Biosciences stock for Q3 2025, up 135% quarter-over-quarter.
- 41 funds opened new Cogent Biosciences positions in Q3 2025 and 24 closed out, a net change of +17 holders.
- The largest Cogent Biosciences buyer in Q3 2025 was Deerfield Management, an estimated $76M added.
- The largest Cogent Biosciences seller in Q3 2025 was Paradigm Biocapital Advisors, an estimated $85.3M sold.
Based on aggregated 13F filings for Q3 2025.